ClinicalTrials.gov
ClinicalTrials.gov Menu

Intra-individual Comparison of Efficacy and Safety of Metvix® Natural Daylight Photodynamic Therapy Versus Conventional Metvix® Photodynamic Therapy in Subject With Mild Actinic Keratoses (CoMet)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01475071
Recruitment Status : Completed
First Posted : November 21, 2011
Results First Posted : April 18, 2016
Last Update Posted : April 18, 2016
Sponsor:
Information provided by (Responsible Party):
Galderma

Brief Summary:
The main objective of this study is to compare efficacy and safety of Metvix® natural daylight photodynamic therapy with those of Metvix® conventional photodynamic therapy with Aktilite™ lamp in subjects with mild actinic keratoses (intra-individual comparison).

Condition or disease Intervention/treatment Phase
Actinic Keratoses Drug: Metvix and natural daylight PDT Drug: Metvix and conventional PDT Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
Official Title: Intra-individual Comparison of Efficacy and Safety of Metvix® Natural Daylight Photodynamic Therapy Versus Conventional Metvix® Photodynamic Therapy in Subject With Mild Actinic Keratoses.
Study Start Date : March 2012
Actual Primary Completion Date : November 2012
Actual Study Completion Date : March 2013

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: Metvix and daylight Drug: Metvix and natural daylight PDT
Methyl aminolevulinate, cream 160mg/g.One session at baseline and a second session administration at week 12 for lesions showing non-complete response and new lesions on target area.
Active Comparator: Metvix and lamp Drug: Metvix and conventional PDT
Methyl aminolevulinate, cream, 160mg/g. One session at baseline and a second session administration at week 12 for lesions showing non-complete response and new lesions on target area.



Primary Outcome Measures :
  1. Lesion Response [ Time Frame: Week12 ]
    Percent of lesions treated at Baseline, in complete response at Week 12

  2. Pain Score [ Time Frame: Baseline (during procedure), assessed after procedure ]
    Subject self assessment of pain on a scale from 0 (no pain ) to 10 (extreme pain)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female above 18 years;
  2. Subject with clinical diagnosis of mild AK on the face or the scalp with or without clinical diagnosis of moderate AK on the target areas (TAs);

Exclusion Criteria:

  1. Subject with clinical diagnosis of at least one severe AK on TAs
  2. Subject with clinical diagnosis of other skin disease (including non-melanoma skin cancer) on the TAs;
  3. Subject with pigmented AK on the TAs

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01475071


Locations
Australia, Australian Capital Territory
Galderma Investigational site
Phillip, Australian Capital Territory, Australia
Australia, New South Wales
Galderma Investigational Site
Kogarah, New South Wales, Australia
Galderma Investigational site
Sydney, New South Wales, Australia
Galderma Investigational site
Westmead, New South Wales, Australia
Australia, Queensland
Galderma Investigational site
Woolloongabba, Queensland, Australia
Australia, Victoria
Galderma Investigational site
Carlton, Victoria, Australia
Sponsors and Collaborators
Galderma
Investigators
Principal Investigator: Stephen Shumack St George Dermatology and skin Cancer Center

Responsible Party: Galderma
ClinicalTrials.gov Identifier: NCT01475071     History of Changes
Other Study ID Numbers: RD.03.SPR.29102
First Posted: November 21, 2011    Key Record Dates
Results First Posted: April 18, 2016
Last Update Posted: April 18, 2016
Last Verified: March 2016

Additional relevant MeSH terms:
Keratosis
Keratosis, Actinic
Skin Diseases
Precancerous Conditions
Neoplasms
Methyl 5-aminolevulinate
Aminolevulinic Acid
Photosensitizing Agents
Dermatologic Agents